# Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma

> **NCT02410733** · PHASE1 · COMPLETED · sponsor: **BioNTech SE** · enrollment: 119 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Lipo-MERIT

## Key facts

- **NCT ID:** NCT02410733
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-06-20
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02410733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02410733, "Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02410733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*